Enliven Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Enliven Therapeutics Inc ELVN.OQ reported a quarterly adjusted loss of 46 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -47 cents. The mean expectation of nine analysts for the quarter was for a loss of 52 cents per share. Wall Street expected results to range from -60 cents to -48 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Enliven Therapeutics Inc's reported EPS for the quarter was a loss of 46 cents​.

• The company reported a quarterly loss of $23.18 million.

• Enliven Therapeutics Inc shares had fallen by 6.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Enliven Therapeutics Inc is $38.00

This summary was machine generated from LSEG data March 13 at 08:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)